Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Heidi Simmons"'
Autor:
Peirong Chen, Shoko Nogusa, Roshan J Thapa, Calvin Shaller, Heidi Simmons, Suraj Peri, Gregory P Adams, Siddharth Balachandran
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61446 (2013)
Metastatic renal cell carcinoma (RCC) is an incurable disease in clear need of new therapeutic interventions. In early-phase clinical trials, the cytokine IFN-γ showed promise as a biotherapeutic for advanced RCC, but subsequent trials were less pro
Externí odkaz:
https://doaj.org/article/237fd204cd484faead81af290962e9d8
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:HSR23-121
Publikováno v:
Psychology of Aesthetics, Creativity, and the Arts. 16:637-650
Publikováno v:
Blood. 140:13102-13104
Autor:
Krish Patel, Jakub Svoboda, Bijal D. Shah, Bruce D. Cheson, Georges Azzi, Kashyap Patel, Andrew J Cowan, Lori Muffly, Heidi Simmons, Mark Schliekelman, Jessica Leonard
Publikováno v:
Blood. 140:5192-5194
Autor:
Heidi Simmons
Publikováno v:
The Journal of Academic Librarianship. 44:279-286
This paper adapts three conceptual frameworks from Environmental Criminology – Routine Activity Theory, Rational Choice Theory, and Situational Crime Prevention – to create a Crime Prevention Toolkit that helps librarians analyze and manage crimi
Autor:
Heidi Simmons, Mark Schliekelman, Cristina Gasparetto, Bijal D. Shah, Lance Baldo, Tomer M Mark, John M. Pagel, Krish Patel, Allison P. Jacob, Michael A. Thompson, Neil Bailey, Jakub Svoboda
Publikováno v:
Blood. 136:37-37
Background: Clinical response data from trials of investigational agents performed over the past several years in various B-cell malignancies has demonstrated significant improvements in the treatment of these diseases. Despite greatly improved overa
Autor:
Selena A Rush, Priscila H. Goncalves, Jennifer Schreiber, Judith A. Carter, Kevin Litwiler, Edward A. Sausville, Dale Roseberry, Heidi Simmons, Lindsay Casetta, Patricia LoRusso, Mieke Ptaszynski
Publikováno v:
Investigational New Drugs. 33:440-449
Purpose Filanesib (ARRY-520) is a highly selective, targeted inhibitor of kinesin spindle protein (KSP) inhibitor that induces mitotic arrest and subsequent tumor cell death. This first-in-human Phase 1 study evaluated dose-limiting toxicities (DLTs)
Autor:
Kevin Litwiler, Guillermo Garcia-Manero, Gautam Borthakur, Selena A Rush, Beverly Bethelmie-Bryan, Hagop M. Kantarjian, Amelia Langston, Heidi Simmons, Martha Arellano, Maria Cielo Foudray, Tapan M. Kadia, Hanna Jean Khoury, Mieke Ptaszynski, Adam I. Marcus, Sharon Karan
Publikováno v:
Cancer. 118:3556-3564
BACKGROUND: ARRY-520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis. METHODS: A phase 1 trial was conducted to establish the safety and the maximum tolerated dose (MTD
Autor:
Gilad Gordon, Gregory Poch, Alex A. Adjei, Heidi Simmons, Suzy Brown, Stephen Leong, Kevin Litwiler, Lia Gore, Katie Kane, S. Gail Eckhardt, Julian R. Molina, David S. Wilson, Lorelei J. Hanson, Laura Q M Chow, Wilbur A. Franklin, Roger B. Cohen, Allison L. Marlow, Jerry Haney, Lara Maloney, Clive Morris
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(13)
Purpose To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer. Patients and Methods In part A, patients